Skip to content
OpenCapital
Get started

GRAIL, Inc. GRAL Accrued clinical studies and research and development expenses

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%—
Debt / equity0×0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept gral:AccruedClinicalStudiesExpensesCurrent.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s accrued clinical studies and research and development expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s accrued clinical studies and research and development expenses?
GRAIL, Inc. (GRAL) reported accrued clinical studies and research and development expenses of $17.82M in Q1 2026.
How has GRAIL, Inc.'s accrued clinical studies and research and development expenses changed year-over-year?
GRAIL, Inc.'s accrued clinical studies and research and development expenses increased by 16.0% year-over-year, from $15.36M to $17.82M.
What is the long-term trend for GRAIL, Inc.'s accrued clinical studies and research and development expenses?
Over 2 years (2023 to 2025), GRAIL, Inc.'s accrued clinical studies and research and development expenses has grown at a 50.7% compound annual growth rate (CAGR), from $6.9M to $15.66M.